2013-03-04 15:12:13 -
GLOSTRUP, Denmark, March 4, 2013 - Dako, an Agilent Technologies Company and
worldwide provider of cancer diagnostics, unveiled the newest addition to its
IHC portfolio at the 2013 USCAP congress in Baltimore, Md., today. As the
exclusive Platinum Sponsor of the congress, Dako used the opportunity to present
its new advanced staining solution to a global gathering of pathologists and lab
The solution, Dako Omnis, comprises hardware, software and reagents. It
automates both IHC and ISH processes, meaning entire patient cases can be
processed simultaneously. This allows pathologists to make quicker, more
informed diagnoses. Oncologists can in turn prescribe relevant therapy with less
anxiety-ridden waiting time for patients.
"This solution provides a breakthrough in addressing some of the hitherto unmet
needs in the anatomic pathology lab," said Dr. Pedro L. Fernandez
Hospital Clinic and University of Barcelona, Spain. "Dako adopted a
collaborative approach to bring this solution to market and cooperated with a
global panel of key independent laboratory personnel. For over three years, we
have been involved in the design and development of this solution. Dako has
really listened and responded to the needs of the customer."
"Our customers tell us they are constantly expected to navigate fluctuating
slide numbers with fewer qualified staff and mounting pressure to provide slides
quickly in order to speed diagnosis," said Lisa Miller, corporate vice president
of Global Commercial Business, Dako.
"With continuous loading, batch loading and overnight run options all available,
Dako Omnis sets new standards for what customers can expect from an automated
platform in terms of flexibility, capacity, efficiency and traceability of
slides," she added.
Dako Omnis provides state-of-the-art software to bring lab control to a new
level. Now, key processes such as slide processing and instrument maintenance
can be traced to individual operators, greatly increasing quality control.
As with all Dako's instruments, customers can use the Dako Link software to
connect all solutions and workstations to the laboratory's own information
system. This approach gives the lab manager even more control over the
processing of each individual slide that enters the lab.
Dako Omnis will be offered as part of Dako's current IHC portfolio, which
includes the Autostainer Link 48 instrument, which Dako will continue to supply
"Each pathology lab is different, and we believe with the addition of Dako Omnis
to our current IHC offering, Dako has an even greater capability to bring the
right solution to the right customer at the right time," said Miller. "Dako has
a reputation for bringing firsts to market, with an unwavering passion for
providing quality solutions. This enables us to offer our customers efficiency,
choice and more time to ultimately provide better patient care. Advancing
pathology is at the heart of what we do, and our customers tell us our new
platform is an important addition."
About Dako - An Agilent Technologies Company
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics.
Hospital and research laboratories worldwide use Dako's reagents, instruments,
software and expertise to make accurate diagnoses and determine the most
effective treatment for cancer patients. Dako, with 1,200 employees, operates in
more than 100 countries. Dako became part of Agilent Technologies on June
21, 2012. Information about Dako is available at www.dako.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company's 20,500 employees serve customers
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.
Director, Science Agenda
Dako Denmark A/S
+45 2933 6980
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE